Company intelligence / Profile preview

Baoyuan Biopharmaceuticals Technology

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Baoyuan reported preclinical data on its next-generation ROS1/NTRK inhibitor AB-106 in Nature Communications, showing potent and selective inhibition of ROS1 and NTRK fusion kinases and activity against resistance mutations, but there is no public evidence of clinical-stage trials yet.[2][7]

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Large and medium-sized biopharma partners (undisclosed; company stated intent to seek such collaborations for its pipeline)[2]

Beyond the preview

Go deeper on Baoyuan Biopharmaceuticals Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Baoyuan Biopharmaceuticals Technology.

Explore the full profile